Core Insights - The collaboration between LaiKai Pharmaceuticals and Qilu Pharmaceutical marks a significant commercialization milestone for LaiKai, focusing on the breast cancer candidate drug LAE002 (afuresertib) in China [1][2] Group 1: Agreement Details - LaiKai Pharmaceuticals has signed an exclusive licensing agreement with Qilu Pharmaceutical for the commercialization of LAE002 in China [1] - The agreement includes a non-refundable upfront payment of up to RMB 530 million and milestone payments for clinical development, totaling up to RMB 2.045 billion [1] - LaiKai will also receive a tiered sales revenue share in China, ranging from over ten percent to over twenty percent [1] Group 2: Product Information - LAE002 (afuresertib) is a potent AKT inhibitor that targets all three AKT isoforms (AKT1, AKT2, and AKT3) and is one of the two AKT inhibitors in late-stage clinical development for breast and prostate cancer globally [2] - The Phase III clinical trial (AFFIRM-205) for LAE002 targeting HR+/HER2- breast cancer is currently recruiting participants as planned [2] - LaiKai aims to complete participant enrollment by Q4 2025 and plans to submit a New Drug Application (NDA) to the China National Medical Products Administration (NMPA) in 2026 [2]

Core Viewpoint - The company has entered into an exclusive licensing agreement with Qilu Pharmaceutical for the research, development, and commercialization of LAE002 (afuresertib) in specified regions of China, which is expected to enhance its financial strength and accelerate the drug's regulatory approval and commercialization process [1][2]. Group 1: Licensing Agreement Details - The licensing agreement grants Qilu Pharmaceutical exclusive rights to LAE002 (afuresertib) in China, including mainland China, Hong Kong, Macau, and Taiwan [1]. - The company will receive a non-refundable upfront payment and milestone payments totaling up to RMB 5.3 billion until the first indication receives new drug application approval in China [1]. - The total potential upfront and milestone payments from the agreement could reach RMB 20.45 billion, along with a tiered sales revenue share ranging from over ten percent to over twenty percent [1]. Group 2: Clinical Development and Strategic Goals - LAE002 (afuresertib) is a potent AKT inhibitor that targets all three AKT isoforms and is one of only two AKT inhibitors in late-stage clinical development for breast and prostate cancer [2]. - The company has initiated the Phase III clinical trial (AFFIRM-205) for HR+/HER2- breast cancer, with recruitment progressing as planned, aiming to complete subject enrollment by Q4 2025 [2]. - The company plans to submit a new drug application to the National Medical Products Administration in China in 2026 [2]. - The board believes that the licensing agreement aligns with the best interests of the company and its shareholders, providing an opportunity to maximize the commercial value of LAE002 (afuresertib) [2]. - The upfront and milestone payments will strengthen the company's financial position to support future developments [2]. - The company is actively engaging with multiple potential partners to establish strategic collaborations to expedite the clinical development and commercialization of its candidate drug assets [2].

Core Viewpoint - The company, Lai Kai Pharmaceutical-B, reported a significant increase in other income and a reduction in losses for the first half of 2025, driven by government subsidies and ongoing clinical trials for its drug candidates targeting metabolic diseases and cancer [1]. Financial Performance - Other income for the first half of 2025 reached RMB 19.9 million, representing a year-on-year increase of 41.1% due to increased government subsidies [1]. - As of June 30, 2025, the company's cash and bank balance amounted to RMB 743.8 million [1]. Clinical Development - The company is focused on developing new therapies for metabolic diseases, cancer, and liver fibrosis, with seven clinical trials initiated for drug candidates LAE102, LAE002 (afuresertib), LAE001, and LAE005 [1]. - In the cancer sector, the company has established a comprehensive portfolio of drug candidates, including LAE002 (afuresertib), which is a potent AKT inhibitor targeting breast and prostate cancers [3]. Research and Development Team - The company has a skilled management team with extensive experience across the entire drug discovery and development cycle, supported by a research team of 60 employees, including 11 PhD holders and 33 master's degree holders [1]. Drug Candidates and Mechanism - LAE102 is positioned as a candidate drug for weight control by promoting muscle regeneration and fat reduction through the inhibition of the Activin-ActRII pathway [2]. - The company is also developing additional candidates, including LAE103 and LAE123, which are selective antibodies targeting ActRII receptors for muscle and other disease indications [2]. Strategic Partnerships - The company plans to seek strategic partnerships to accelerate the development and commercialization of its drug candidates, addressing significant unmet medical needs [3].